INFO - Enbrel, Humira, and Remicade - human or mouse?

[Guest guest]

s Hopkins Arthritis Center

" Rheumatoid Arthritis Treatment " :

http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_treat\

..html

Enbrel (etanercept)

Etanercept is effective in reducing the signs and symptoms of RA, as

well as in slowing or halting radiographic damage, when used either as

monotherapy or in combination with methotrexate. Etanercept is also

approved for the treatment of psoriatic arthritis and for ankylosing

spondylitis as well as psoriasis. Etanercept is a fusion protein that

combines two extracellular binding domains of the p75 form of the TNF

receptor with the Fc portion of a human IgG1 antibody molecule. The

components of the protein are entirely human, and anti-etanercept

antibodies are relatively uncommon.

Humira (adalimumab)

Adalimumab is a fully human anti-TNF monoclonal antibody with high

specificity for TNF. Like the other TNF antagonists, it is effective

as monotherapy and in combination with methotrexate, at reducing signs

and symptoms of RA and in slowing or halting radiographic progression

of disease. It is administered by subcutaneous injection every two

weeks but can be increased to weekly, if needed. Adalimumab is

effective in RA, Psoriatic arthritis, and ankylosing spondylitis, and

Crohn’s disease.

Mechanism:

Adalimumab binds specifically to TNF and blocks its interaction with

the p55 and p75 cell surface TNF receptors, thereby interfering with

endogenous TNF activity. Adalimumab binds to both soluble as well as

cell bound TNF.

Remicade (infliximab)

Infliximab, in combination with methotrexate, is approved for the

treatment of RA, and for the treatment of psoriatic arthritis, and

ankylosing spondylitis, as well as psoriasis and Crohn’s disease.

Infliximab is a chimeric monoclonal antibody that binds TNF with high

affinity and specificity. The antibody binding site for TNF is of

mouse origin, with the remaining 75% of the infliximab antibody

derived from a human IgG1 antibody sequence.

Not an MD

[Guest guest]

It's sort of skeevy to see it in print. Even " entirely human " could have some

gruesome implications. Oh well, as the previous posted said, I'll take it and

try not to think too much about it. It works like magic for me and that's what

counts.

Kate F

________________________________

From: <Rheumatoid.Arthritis.Support@...>

< >

Sent: Wed, May 19, 2010 4:33:27 PM

Subject: [ ] INFO - Enbrel, Humira, and Remicade - human or mouse?

s Hopkins Arthritis Center

" Rheumatoid Arthritis Treatment " :

http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_treat\

..html

Enbrel (etanercept)

Etanercept is effective in reducing the signs and symptoms of RA, as

well as in slowing or halting radiographic damage, when used either as

monotherapy or in combination with methotrexate. Etanercept is also

approved for the treatment of psoriatic arthritis and for ankylosing

spondylitis as well as psoriasis. Etanercept is a fusion protein that

combines two extracellular binding domains of the p75 form of the TNF

receptor with the Fc portion of a human IgG1 antibody molecule. The

components of the protein are entirely human, and anti-etanercept

antibodies are relatively uncommon.

Humira (adalimumab)

Adalimumab is a fully human anti-TNF monoclonal antibody with high

specificity for TNF. Like the other TNF antagonists, it is effective

as monotherapy and in combination with methotrexate, at reducing signs

and symptoms of RA and in slowing or halting radiographic progression

of disease. It is administered by subcutaneous injection every two

weeks but can be increased to weekly, if needed. Adalimumab is

effective in RA, Psoriatic arthritis, and ankylosing spondylitis, and

Crohn’s disease.

Mechanism:

Adalimumab binds specifically to TNF and blocks its interaction with

the p55 and p75 cell surface TNF receptors, thereby interfering with

endogenous TNF activity. Adalimumab binds to both soluble as well as

cell bound TNF.

Remicade (infliximab)

Infliximab, in combination with methotrexate, is approved for the

treatment of RA, and for the treatment of psoriatic arthritis, and

ankylosing spondylitis, as well as psoriasis and Crohn’s disease.

Infliximab is a chimeric monoclonal antibody that binds TNF with high

affinity and specificity. The antibody binding site for TNF is of

mouse origin, with the remaining 75% of the infliximab antibody

derived from a human IgG1 antibody sequence.

Not an MD

------------------------------------